Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Dose Ranging Study to Evaluate Safety and Tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in Subjects With Advanced Age-Related Macular Disease

NCT00102115 is registered in ClinicalTrials.gov with Light Sciences LLC as lead sponsor.

NCT NCT00102115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Dose Ranging Study to Evaluate Safety and Tolerability of Talaporfin Sodium (LS11) Photodynamic Therapy in Subjects With Advanced Age-Related Macular Disease
Lead sponsor
Light Sciences LLC
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2004
Completion date
January 31, 2006
Enrollment
27
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascularization, macular degeneration